MetaCap

Invivyd (IVVD) vs Sutro Biopharma (STRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sutro Biopharma (STRO) has outperformed Invivyd (IVVD) over the past year, gaining 2.4% versus a loss of 83.5%. Over five years, STRO leads with a -94.7% price change compared with -98.4% for IVVD. Sutro Biopharma is the larger company by market cap ($142.8 million vs $122.0 million), about 1.2 times the size, while Invivyd is growing revenue faster (+110.5% vs +65.2%).

Invivyd converts more of its revenue into profit, with a net margin of -98.2% versus -186.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IVVD-83.49%STRO+2.38%
+411%+152%-107%
Nov 21, 20251 yearNov 20, 2026
IVVD-97.94%STRO-95.10%
+140%+15%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IVVD versus STRO key metrics
MetricIVVDSTRO
Share price$0.4127$8.60
Market cap$122.01M$142.77M
1-day change-7.45%-1.38%
YTD return-83.29%-25.67%
1-year return-83.49%+2.38%
5-year return-98.36%-94.68%
EPS (TTM)$-0.38$-12.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$53.43M$102.48M
Revenue growth (YoY)+110.47%+65.18%
Net income (latest FY)$-52.49M$-191.09M
Operating margin-103.99%-154.53%
Net margin-98.25%-186.45%
52-week high$3.01$43.85
52-week low$0.4127$7.15
Distance from 52-week high-86.29%-80.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+2323.07%+419.65%
Average volume5.20M304.90K
Shares outstanding295.63M16.60M
Employees122129
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STRO has outperformed IVVD by 85.9 percentage points over the past year.
  • Invivyd is more profitable, keeping -98.2 cents of every revenue dollar as net income versus -186.5 cents for Sutro Biopharma.
  • Invivyd grew revenue faster in its latest fiscal year (+110.47% vs +65.18%).

About Invivyd

IVVD stock →

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees

About Sutro Biopharma

STRO stock →

Sutro Biopharma, Inc. operates as an oncology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees

IVVD vs STRO FAQ

Which is bigger, Invivyd or Sutro Biopharma?

Sutro Biopharma (STRO) is larger, with a market capitalization of $142.77M compared with $122.01M for Invivyd (IVVD).

Which stock has performed better over the past year, IVVD or STRO?

STRO returned +2.38% over the past 12 months, compared with -83.49% for IVVD (price return, excluding dividends). Past performance does not predict future results.

Are Invivyd and Sutro Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons